Novo reports ‘really powerful’ cardio, death risk reduction for semaglutide in kidney disease

No­vo Nordisk’s semaglu­tide cut the risk of ma­jor car­dio­vas­cu­lar events and death from mul­ti­ple caus­es in a Phase 3 study in­volv­ing pa­tients with type 2 di­a­betes and chron­ic kid­ney dis­ease, build­ing the com­pa­ny’s case for ex­pand­ing the drug in a broad range of in­di­ca­tions.

The da­ta, which cap­tured sec­ondary end­points of the FLOW study, were pre­sent­ed Fri­day at the Eu­ro­pean Re­nal As­so­ci­a­tion’s con­fer­ence and pub­lished in the New Eng­land Jour­nal of Med­i­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.